Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 784

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 784
---
 Company’s Board of Directors for their Board service during the three months ended September 30, 2023 was $26.88, and during the nine months ended September 30, 2024 and 2023 was $7.92 and $70.32, respectively. No options were granted to non-employee consultants during the three and nine months ended September 30, 2024 and 2023. During the three and nine months ended September 30, 2024 and 2023, the Company recognized compensation expense relating to stock options as follows:

| ​                          
 ​                          | ​ 
 ​ | ​ 
 ​ | Three Months EndedSeptember 30, 
 2024                            |   |       |   | ​ | ​ | 2023 |   |       |   | ​ 
 ​ | ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           |   |       |   | ​ | ​ | 2023 |   |       |   | ​ 
 ​ |
|:---------------------------|:--|:--|:--------------------------------|:--|------:|:--|:--|:--|:-----|:--|------:|:--|:--|:--|:-------------------------------|:--|------:|:--|:--|:--|:-----|:--|------:|:--|:--|
| Research and development   | ​ | ​ | ​                               | $ |    16 | ​ | ​ | ​ | ​    | $ | 1,387 | ​ | ​ | ​ | ​                              | $ |   795 | ​ | ​ | ​ | ​    | $ | 4,314 | ​ | ​ |
| General and administrative | ​ | ​ | ​                               | ​ | 1,120 | ​ | ​ | ​ | ​    | ​ | 1,447 | ​ | ​ | ​ | ​                              | ​ | 3,494 | ​ | ​ | ​ | ​    | ​ | 4,122 | ​ | ​ |
| Total stock option expense | ​ | ​ | ​                               | $ | 1,136 | ​ | ​ | ​ | ​    | $ | 2,834 | ​ | ​ | ​ | ​                              | $ | 4,289 | ​ | ​ | ​ | ​    | $ | 8,436 | ​ | ​ |

A summary of stock option award activity related to employees